Shearman & Sterling represented Genmab A/S in connection with an underwritten private placement of 4,600,000 of its ordinary shares for aggregate gross proceeds of $180 million. The private placement included sales to institutional investors in Denmark and internationally. Jefferies International Limited and Kempen & Co N.V. acted as co-managers for the private placement. The proceeds from the private placement will be used to further develop Genmab’s clinical and pre-clinical pipeline.

Founded in Copenhagen, Denmark in 1999, Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Genmab’s shares are listed on the NASDAQ OMX Copenhagen.

The Shearman & Sterling team included partner Robert Treuhold (New York-Capital Markets); counsel Harald Halbhuber (New York-Capital Markets); and associates James Park (New York-Capital Markets) and Reed Schuster (New York-Capital Markets).